{"title":"Research progress of mammalian target of rapamycin and occurence of autoimmune hemolytic anemia","authors":"Y. Wang","doi":"10.3760/CMA.J.ISSN.1673-419X.2019.06.014","DOIUrl":null,"url":null,"abstract":"Mammalian target of rapamycin (mTOR) is a serine/threonine protein kinase that is involved in the immune pathogenesis of autoimmune hemolytic anemia (AIHA) by regulating different types of T cell, B cells and dendritic cells (DC). mTOR inhibitor acts on the mTOR signaling pathway. It can up-regulate the number of regulatory T cell (Treg) and down-regulate the number of helper T cell (Th), Th2, and Th17. It plays an important role in the treatment of recurrent/refractory AIHA. The authors review the molecular structure of mTOR, mTOR signaling pathway, the regulation of mTOR involved in immune cells, and the treatment of AIHA with mTOR inhibitors. \n \n \nKey words: \nTOR serine-threonine kinases; Anemia, hemolytic, autoimmune; T-lymphocytes, regulatory; Th1 cells; Molecular targeted therapy; Immunosuppressive agents","PeriodicalId":13774,"journal":{"name":"国际输血及血液学杂志","volume":"42 1","pages":"543-547"},"PeriodicalIF":0.0000,"publicationDate":"2019-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"国际输血及血液学杂志","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3760/CMA.J.ISSN.1673-419X.2019.06.014","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Mammalian target of rapamycin (mTOR) is a serine/threonine protein kinase that is involved in the immune pathogenesis of autoimmune hemolytic anemia (AIHA) by regulating different types of T cell, B cells and dendritic cells (DC). mTOR inhibitor acts on the mTOR signaling pathway. It can up-regulate the number of regulatory T cell (Treg) and down-regulate the number of helper T cell (Th), Th2, and Th17. It plays an important role in the treatment of recurrent/refractory AIHA. The authors review the molecular structure of mTOR, mTOR signaling pathway, the regulation of mTOR involved in immune cells, and the treatment of AIHA with mTOR inhibitors.
Key words:
TOR serine-threonine kinases; Anemia, hemolytic, autoimmune; T-lymphocytes, regulatory; Th1 cells; Molecular targeted therapy; Immunosuppressive agents
期刊介绍：
The International Journal of Transfusion and Hematology was founded in September 1978. It is a comprehensive academic journal in the field of transfusion and hematology, supervised by the National Health Commission and co-sponsored by the Chinese Medical Association, West China Second Hospital of Sichuan University, and the Institute of Transfusion Medicine of the Chinese Academy of Medical Sciences. The journal is a comprehensive academic journal that combines the basic and clinical aspects of transfusion and hematology and is publicly distributed at home and abroad. The International Journal of Transfusion and Hematology mainly reports on the basic and clinical scientific research results and progress in the field of transfusion and hematology, new experiences, new methods, and new technologies in clinical diagnosis and treatment, introduces domestic and foreign research trends, conducts academic exchanges, and promotes the development of basic and clinical research in the field of transfusion and hematology.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
